Currently, some available biomarkers such as PSA (prostate-specific antigen) for prostate cancer, CEA (carcinoembryonic antigen) for colorectal cancer, AFP (a-fetoprotein) for liver cancer, CA 125 for ovarian cancer, and CA 19–9 for pancreatic cancer invariably display an inferior sensitivity and specificity, despite their generally clinical applications. The gene discussed is KLK3; the disease is liver cancer.